| abstract |
The invention relates to a pharmaceutical composition comprising an HMG CoA reductase inhibitor (E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] - (3R. 5S) -3,5-dihydroxyhept-6-eic acid or a pharmaceutically acceptable salt thereof as an active ingredient which remains stable over a long period. The invention relates to a pharmaceutical composition comprising an HMG CoA reductase inhibitor (E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] - (3R. 5S) -3,5-dihydroxyhept-6-eic acid or a pharmaceutically acceptable salt thereof as an active ingredient which remains stable over a long period. |